Enovis Corp (ENOV) - Total Liabilities

Latest as of March 2026: $2.35 Billion USD

Based on the latest financial reports, Enovis Corp (ENOV) has total liabilities worth $2.35 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Enovis Corp to track the company's year-over-year net asset growth rate.

Enovis Corp - Total Liabilities Trend (2004–2025)

This chart illustrates how Enovis Corp's total liabilities have evolved over time, based on quarterly financial data. See ENOV cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Enovis Corp Competitors by Total Liabilities

The table below lists competitors of Enovis Corp ranked by their total liabilities.

Company Country Total Liabilities
General American Investors Closed Fund
NYSE:GAM
USA $17.73 Million
Blackrock Municipal Target Term Closed Fund
NYSE:BTT
USA $838.63 Million
Origin Bancorp, Inc.
NYSE:OBK
USA $8.93 Billion
Geo-Jade Petroleum Corp
SHG:600759
China CN¥3.99 Billion
China Resources Chemical Innovative Materials Co. Ltd.
SHE:301090
China CN¥2.13 Billion
Guangzhou Zhiguang Electric Co Ltd
SHE:002169
China CN¥7.34 Billion
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
USA $25.32 Million
Arteris Inc
NASDAQ:AIP
USA $129.66 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Enovis Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ENOV company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.59 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.61 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enovis Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enovis Corp (2004–2025)

The table below shows the annual total liabilities of Enovis Corp from 2004 to 2025.

Year Total Liabilities Change
2025-12-31 $2.34 Billion +8.74%
2024-12-31 $2.15 Billion +97.90%
2023-12-31 $1.09 Billion +32.20%
2022-12-31 $823.45 Million -78.64%
2021-12-31 $3.85 Billion +2.41%
2020-12-31 $3.76 Billion -3.43%
2019-12-31 $3.90 Billion +24.63%
2018-12-31 $3.13 Billion +4.43%
2017-12-31 $2.99 Billion -9.04%
2016-12-31 $3.29 Billion -5.30%
2015-12-31 $3.48 Billion -10.69%
2014-12-31 $3.89 Billion +1.33%
2013-12-31 $3.84 Billion -3.31%
2012-12-31 $3.97 Billion +341.85%
2011-12-31 $899.27 Million +11.61%
2010-12-31 $805.71 Million +0.17%
2009-12-31 $804.30 Million +7.79%
2008-12-31 $746.14 Million -11.54%
2007-12-31 $843.49 Million +6.59%
2006-12-31 $791.33 Million +11.75%
2005-12-31 $708.15 Million +16.13%
2004-12-31 $609.79 Million --

About Enovis Corp

NYSE:ENOV USA Medical Devices
Market Cap
$1.74 Billion
Market Cap Rank
#7410 Global
#2221 in USA
Share Price
$30.18
Change (1 day)
-2.20%
52-Week Range
$20.04 - $33.32
All Time High
$91.10
About

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more